94 related articles for article (PubMed ID: 28065418)
1. Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Vis DJ; Srinivas S; Morales-Barrera R; Carles J; Al-Rimawi D; Lee S; Kim KH; Izumi K; Lewin J
Clin Genitourin Cancer; 2017 Aug; 15(4):e563-e571. PubMed ID: 28065418
[TBL] [Abstract][Full Text] [Related]
2. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
3. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
5. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
[TBL] [Abstract][Full Text] [Related]
6. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
7. Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Tsang ES; Forbes C; Chi KN; Eigl BJ; Parimi S
Curr Oncol; 2019 Apr; 26(2):e260-e265. PubMed ID: 31043835
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
Locke JA; Pond GR; Sonpavde G; Necchi A; Giannatempo P; Paluri RK; Niegisch G; Albers P; Buonerba C; Di Lorenzo G; Vaishampayan UN; North SA; Agarwal N; Hussain SA; Pal S; Eigl BJ
Clin Genitourin Cancer; 2016 Aug; 14(4):331-40. PubMed ID: 26589729
[TBL] [Abstract][Full Text] [Related]
9. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
10. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Necchi A; Pond GR; Pal SK; Agarwal N; Bowles DW; Plimack ER; Yu EY; Ladoire S; Baniel J; Crabb S; Niegisch G; Srinivas S; Berthold DR; Rosenberg JE; Powles T; Bamias A; Harshman LC; Bellmunt J; Galsky MD;
Clin Genitourin Cancer; 2018 Apr; 16(2):e483-e490. PubMed ID: 29158079
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Necchi A; Pond GR; Raggi D; Giannatempo P; Vogelzang NJ; Grivas P; Galsky MD; Bellmunt J; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):23-30.e2. PubMed ID: 27324051
[TBL] [Abstract][Full Text] [Related]
12. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
[TBL] [Abstract][Full Text] [Related]
13. Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer.
Santoni M; Crabb SJ; Conti A; Rossi L; Burattini L; Conteduca V; Chau C; Burgio SL; Muzzonigro G; Cascinu S; De Giorgi U
Clin Genitourin Cancer; 2015 Jun; 13(3):244-9. PubMed ID: 25465492
[TBL] [Abstract][Full Text] [Related]
14. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
[TBL] [Abstract][Full Text] [Related]
15. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
[TBL] [Abstract][Full Text] [Related]
16. Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan.
Matsumoto R; Abe T; Ishizaki J; Kikuchi H; Harabayashi T; Minami K; Sazawa A; Mochizuki T; Akino T; Murakumo M; Osawa T; Maruyama S; Murai S; Shinohara N
Jpn J Clin Oncol; 2018 Aug; 48(8):771-776. PubMed ID: 29939285
[TBL] [Abstract][Full Text] [Related]
17. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Pond GR; Agarwal N; Bellmunt J; Choueiri TK; Qu A; Fougeray R; Vaughn D; James ND; Salhi Y; Albers P; Niegisch G; Galsky MD; Wong YN; Ko YJ; Stadler WM; O'Donnell PH; Sridhar SS; Vogelzang NJ; Necchi A; Di Lorenzo G; Sternberg CN; Mehta A; Sonpavde G
BJU Int; 2014 May; 113(5b):E137-43. PubMed ID: 24219029
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
20. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
